Noncarbapenems for the Treatment of Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Bacteria

Southern Medical Journal
C Whitney WhiteJacob Campbell

Abstract

Urinary tract infections (UTIs) caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae are resistant to many conventional therapies, including third-generation cephalosporins. Carbapenems are considered first-line agents for ESBL infections, but their use is associated with increased multidrug resistance and should be reserved when absolutely necessary. Because of the increased rates of UTIs caused by ESBL-producing organisms and incidence of carbapenem resistance, safe and effective alternatives to carbapenems are needed. This study was conducted to evaluate the outcomes associated with the treatment of ESBL UTIs with noncarbapenem antibiotics. A retrospective cohort study of adults with ESBL UTIs was conducted at a community hospital. Patients were categorized as those receiving definitive carbapenem therapy and those receiving definitive noncarbapenem therapy. Calculated measurements included infection-related mortality, length of hospital stay, and duration of definitive antibiotic therapy. Microbiological failure was assessed as a secondary outcome. Data on the safety of antibiotic therapy were not collected. P < 0.05 was considered significant. Fifty patients met inclusion criteria for the study, divi...Continue Reading

References

Jun 19, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Patricia A BradfordJohn Quale
Feb 23, 2008·The Lancet Infectious Diseases·Johann D D Pitout, Kevin B Laupland
Sep 24, 2008·Archives of Internal Medicine·Jesús Rodríguez-BañoAlvaro Pascual
Oct 12, 2010·Journal of Global Infectious Diseases·Deepti Rawat, Deepthi Nair
Nov 15, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Yohei DoiDavid L Paterson
Feb 26, 2013·Médecine et maladies infectieuses·D FournierX Bertrand
Aug 24, 2013·The Lancet Infectious Diseases·L Silvia Munoz-PriceJohn P Quinn
Sep 3, 2014·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Tumay IpekciOrcun Celik
Dec 3, 2014·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Takanori AsakuraSatoshi Kodera
Jan 16, 2016·The Korean Journal of Internal Medicine·Sung-Yeon ChoJin-Hong Yoo
May 29, 2016·International Journal of Antimicrobial Agents·Michael P VeveSusan L Davis
Jun 18, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Florian M WagenlehnerLeanne B Gasink
Sep 13, 2018·JAMA : the Journal of the American Medical Association·Patrick N A HarrisUNKNOWN MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN)

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.